5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride
Basic information
- CAS
122852-69-1- Standard SMILES
Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O.[Cl-].[H+]- InChIKey
FNYQZOVOVDSGJH-UHFFFAOYSA-N- Molecular formula
- C17H19ClN4O
- Average molar mass
- 330.8 g/mol
- Monoisotopic mass
- 330.1247389
Overview
Alosetron hydrochloride is the hydrochloride salt of alosetron. It has a role as a serotonergic antagonist and an antiemetic. It contains an alosetron.
Names & identifiers
- Preferred name
- 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride
- IUPAC
- hydron;5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one;chloride
- English name
- Alosetron hydrochloride
- Molecular formula
- C17H19ClN4O
- Molecular weight
- 330.81
Names & synonyms
5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochlorideSCHEMBL635233AKOS026750525ALOSETRON HCLLotronexGR 68755GR 68755XGR 68755CAlosetron hydroclorideALOSETRON HYDROCHLORIDEAlosetron HCl - Bio-X ?Alosetron hydrochloride salt
Show more names
Alosetron hydrochloride USP/EP/BP
Database identifiers
- CAS
122852-69-1- PubChem CID
- 44558893
- ChEBI
CHEBI:53783
Properties
Computed structural properties
- Topological polar surface area
- 53.9 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 3
- Rotatable bonds
- 2
- Heavy atoms
- 23
- Formal charge
- 0
- Complexity
- 442
Physicochemical properties
- Melting point
- 288 · 288-291°C
- storage temp.
- 2 · 2-8°C
- solubility
- 2 O: · H2O: ≥5mg/mL at warmed
- form
- powder
- color
- white to beige
- Water Solubility
- 2 O: · H2O: ≥5mg/mL atwarmed
- InChI
- 1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H
- InChIKey
- FNYQZOVOVDSGJH-UHFFFAOYSA-N
- SMILES
- CN1C2=C(C=CC=C2)C3=C1CCN(CC4=C(C)N=CN4)C3=O.Cl
- CAS DataBase Reference
- 122852 · 122852-69-1(CAS DataBase Reference)
- FDA UNII
- 2 F5R1A46YW · 2F5R1A46YW
- UNSPSC Code
- 41116107 · 41116107
- NACRES
- 77 · NA.77
- Symbol(GHS)
- 6 · GHS06
- Signal word
- Danger
- Hazard statements
- 301 · H301-H319-H412
- Precautionary statements
- 273 · P273-P301+P310+P330-P305+P351+P338
- Hazard Codes
- T,Xi
- Risk Statements
- 25 · 25-36-52/53
- Safety Statements
- 26 · 26-45
- RIDADR
- 2811 · UN 2811 6.1 / PGIII
- WGK Germany
- 3 · 3
- HS Code
- 2933790002 · 2933790002
- Storage Class
- 6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- Hazard Classifications
- 3 OralAquatic · Acute Tox. 3 OralAquatic Chronic 3Eye Irrit. 2
- Hazardous Substances Data
- 122852 · 122852-69-1(Hazardous Substances Data)
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- wgk
- 3
- ridadr
- UN 2811 6.1 / PGIII
- hs_code
- 2933790002
- risk_code
- 25-36-52/53
- Signal word
- Danger
- Symbol(GHS)
- GHS06
- hazard_code
- T,Xi
- safety_code
- 26-45
- Storage Class
- 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- Hazard statements
- H301-H319-H412
- Hazard Classifications
- Acute Tox. 3 OralAquatic Chronic 3Eye Irrit. 2
- Precautionary statements
- P273-P301+P310+P330-P305+P351+P338
- Hazardous Substances Data
- 122852-69-1(Hazardous Substances Data)
Chemistry & industry
Applications
DescriptionLotronex (alosetron) was developed for the treatment of severe irritable bowel syndrome (IBS), and was approved for use by the US Food and Drug Administration (FDA) in 2000. Although Lotronex had a relatively high improvement rate in patients taking the drug for IBS, it was voluntarily pulled from the market by GlaxoWellcome that same year due to reports of severe adverse side effects, some resulting in death. In 2002, Lotronex was reapproved in a supplemental New Drug Application for use under more restrictive conditions. Now with a risk management program to be consulted prior to administration of the drug, Lotronex is designated to be prescribed only when its medical benefits outweigh the risks of toxic effects; women with severe diarrhea-predominant IBS are now the focal point of prescriptions for Lotronex.
UsesLotronex is used for severe diarrhea-predominant IBS in women. There are other potential uses, as animal models have shown at least some evidence for the ability of Lotronex to mitigate the effects of psychosis, anxiety, cognitive impairment, emesis, and drug withdrawal. These possibilities have not been verified in humans, however.
UsesAlosetron hydrochloride is used in treatment of irritable bowel syndrome
Upstream & downstream products
Upstream raw materials
Additional notes
DefinitionChEBI: The hydrochloride salt of alosetron.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…